254 results
6-K
EX-99.1
THTX
Theratechnologies Inc.
9 May 24
Theratechnologies Reports on its Annual Meeting of Shareholders
5:26pm
. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative … and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s
6-K
EX-99.2
THTX
Theratechnologies Inc.
15 Apr 24
Notice of Annual Meeting of Shareholders
9:31am
for Canada, Chief Marketing Officer for the U.S. in Primary Care and as Regional President in Asia-Pacific for the innovative division of Pfizer.
He also
6-K
EX-99.2
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
are a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.
Our business … of high unmet need, including innovative medicines in oncology and NASH. The Company’s research & development activities also works on extending
6-K
EX-99.1
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
)
Theratechnologies Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical
6-K
EX-99.1
THTX
Theratechnologies Inc.
10 Apr 24
Theratechnologies Reports Financial Results
8:16am
” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today … ) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about
6-K
EX-99.1
0665qe 28xtpou
5 Apr 24
Theratechnologies Appoints Elina Tea to its Board of Directors
12:57pm
6-K
EX-99.1
eg7p63c31ts ncr
22 Mar 24
Theratechnologies Announces Update on its Preclinical Oncology Research Program
4:27pm
6-K
EX-99.1
7txjb
22 Mar 24
Theratechnologies Appoints Jordan Zwick to its Board of Directors
1:37pm
6-K
EX-99.1
zf4te 79ve3bytz1b
21 Mar 24
Current report (foreign)
12:40pm
6-K
EX-99.1
buaq1ix3xqhlmfn jtp4
29 Feb 24
Theratechnologies Announces the Resignation of One of Its
4:55pm
6-K
EX-99.1
u7rfb o540rfdr
27 Feb 24
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular
8:37am
6-K
EX-99.1
fhpndovh f4pr
21 Feb 24
Theratechnologies Reports Financial Results
8:00am
6-K
EX-99.1
turbbmne5mgpr1
15 Feb 24
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
8:36am
6-K
EX-99.1
0vczgg6h7nsv06in
6 Feb 24
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial
2:29pm
6-K
EX-99.1
tutga6ck6
24 Jan 24
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
1:52pm
6-K
EX-99.1
vstby
23 Jan 24
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental
2:01pm
6-K
EX-99.1
pyrw4b ftp
21 Dec 23
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
4:24pm
6-K
EX-99.1
nmp6a1c6b1noxnq02
13 Dec 23
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
2:41pm
6-K
EX-99.1
cbrfgol94z47fyna
31 Oct 23
Theratechnologies Announces Closing of US$25 Million Public Offering of
12:51pm